Non-Surgical Treatment Gives Lung Cancer Patients Three Years or More

	Tweet

Fifty-seven percent of lung cancer patients who were treated with thermal ablation survived to three years, two years beyond average life expectancy, according to research in the July issue of the Journal of Vascular and Interventional Radiology (JVIR). The patients had early-stage, I-II, non-small cell lung cancer (NSCLC). During thermal ablation, an interventional radiologist uses imaging to guide a small needle through the skin into the tumor. Energy is then transmitted to the tip of the needle to “cook” and kill the tumor with heat or “freeze” it with cold.

“Only one-third of patients diagnosed with non-small cell lung cancer are eligible for surgery - the rest face the reality of having less than 12 months to live,” states study author Damian Dupuy, M.D., of Rhode Island Hospital. “These new outpatient treatments not only are effective, but allow us to treat patients who historically have no other options. Utilizing imaging and targeted thermal ablation, we can heat and destroy lung tumors, and extend a patients life. As a physician, it’s so gratifying to be able to provide a treatment that is so beneficial to patients and so easy for them to undergo.”

The purpose of this study was to evaluate the clinical outcomes of patients with early-stage NSCLC after combined treatment with thermal ablation and radiotherapy, and it showed that the combination therapy may result in an improved survival over either modality alone.

About the Study
The patients in the study were terminal, with a life expectancy of less than one year, and were not surgical candidates according to the oncology team which consisted of a pulmonologist, medical oncologist, radiation oncologist and thoracic surgeon. Twenty-seven of the patients who underwent thermal ablation subsequently received external-beam radiation, the primary treatment in patients who are considered poor operative candidates. Fourteen patients underwent thermal ablation followed by interstitial brachytherapy, which is radiation therapy given internally to the tumor with a catheter. Of the 41 patients, 97.6% survived to six months, 86.8% to one year, 70.4% to two years and 57.1% to three years. The median follow-up was 19.5 months with an average survival of 42.2 months. The patients with tumors smaller than 3 cm (n=17) had the best outcomes, with an average survival of 44.4 months.

About Thermal Ablation
Tumors need a blood supply, which they actively generate, to feed themselves and grow. As vascular experts, interventional radiologists are uniquely skilled in using the vascular system to deliver targeted treatments via catheter throughout the body or percutaneously through the skin. In treating cancer patients, interventional radiologists can attack the cancer tumor from inside the body without medicating or affecting other parts of the body. These minimally-invasive treatments are much easier on the patient than systemic therapy. Thermal ablation can be given without affecting the patient’s overall health and most people can resume their usual activities in a few days. The treatment usually does not require general anesthesia and is typically performed on an outpatient basis. Thermal ablation treatments are a growing area in interventional oncology, a specialty area of medicine within interventional radiology. In this study, the two types of thermal ablation used were radiofrequency and microwave.

Radiofrequency ablation (RFA) offers a non-surgical, localized treatment that kills the tumor cells with heat, while sparing the healthy lung tissue. During the procedure, the interventional radiologist guides a small needle through the skin into the tumor. From the tip of the needle, radiofrequency (electrical) energy is transmitted to the tip of the needle, where it produces heat in the tissues. The dead tumor tissue shrinks and slowly forms a scar. In a small number of cases, RFA can extend patients’ lives, but it is generally palliative. Depending on the size of the tumor, RFA can shrink or kill the tumor, extending the patient’s survival time and greatly improving their quality of life while living with cancer.

Microwave ablation utilizes electromagnetic microwaves to agitate the water molecules in the tumor and surrounding tissue, ultimately reversing the cells’ polarity. This change in polarity causes the cells to rotate back and forth, causing friction and heat which kills the cell (coagulation necrosis).

Society of Interventional Radiology (SIR)

RELATED STORIES:
Lung cancer tied to family risk of other cancers   Gene Expression Profiling Not Quite Perfected in Predicting Lung Cancer Prognosis   Gene fusion in lung cancer afflicting never-smokers may be target for therapy   Long-Term Use of Nutrient Supplements May Increase Cancer Risk   Gold nanotech breath test may show lung cancer early   Genetic Region Linked to a Five Times Higher Lung Cancer Risk   Ovary removal may raise risk of lung cancer   Quitting Smoking After Lung Cancer Diagnosis Can Prolong Life   Passive Smoke in Workplace Increases Lung Cancer Risk   Lung cancer patients fight stigma   Exercise Can Reduce a Smoker’s Lung Cancer Risk, but Quitting Still Most Important   Gene test helps predict lung cancer, study finds   Researchers surprised to find no link between marijuana, lung cancer   Radiation-Armed Robot Rapidly Destroys Human Lung Tumors   New lung cancer drug shows dramatic results for shrinking tumors   Lymph node dissection is not essential in small screen-detected lung cancers, new research shows   Advances in lung cancer research announced at conference   Missing protein may hold lung cancer key   Reduced lung function tied to lung cancer risk   Lung cancer death rates in lifelong non-smokers   Survey finds significant racial differences in lung cancer beliefs   BATTLE Trial Personalizes Lung Cancer Therapy

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]